Skip to main content
Search
Audio Interview

Translational medicine: the risk of failure in delay and how to reduce it

Published on September 12, 2022   30 min

A selection of talks on Pharmaceutical Sciences

Please wait while the transcript is being prepared...
0:00
Interviewer: Today I'm interviewing Dr. Martin Wehling, Director at the Institute for Clinical Pharmacology, University of Heidelberg, and editor of, "Principles of Translational Science in Medicine from Bench to Bedside", published by Amazon press and in its third edition. The subject of this interview is, what are the big risks of failure in delay in getting from the bench to clinic, and how can they be reduced? Dr. Wehling, thank you for sparing the time for this interview. One big question with three interconnecting parts, what are the risks of failure, how to reduce them and still develop novel profitable products? What advice would you give to CEOs, Chief Science Officers, and Chief Finance Officers, Professor Wehling? Prof. Wehling: The biggest risk is that you don't understand the underlying disease. This is the ultimate problem. I`ll give you an example to start. With Alzheimer's disease, we had many, many interventions to reduce what was obviously wrong with Alzheimer's patients. Namely, beta-amyloid. But reducing it, at least in 20 trials, didn't help the patients. We found out that we looked at the wrong epiphenomenon of the disease because we did not understand the disease. This is the clue to success to begin with. Other problems are, when we start a project, we only rely on test tubes
Show
Hide

Translational medicine: the risk of failure in delay and how to reduce it

Embed in course/own notes